Strategies for Using Antigen Rapid Diagnostic Tests to Reduce Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Low- and Middle-Income Countries: A Mathematical Modelling Study Applied to Zambia

被引:12
作者
Han, Alvin X. [1 ]
Girdwood, Sarah J. [2 ]
Khan, Shaukat [3 ]
Sacks, Jilian A. [4 ]
Toporowski, Amy [4 ]
Huq, Naushin [4 ]
Hannay, Emma [4 ]
Russell, Colin A. [1 ,5 ]
Nichols, Brooke E. [1 ,2 ,4 ,5 ]
机构
[1] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Med Microbiol & Infect Prevent, Amsterdam, Netherlands
[2] Univ Witwatersrand, Hlth Econ & Epidemiol Res Off, Dept Internal Med, Sch Clin Med,Fac Hlth Sci, Johannesburg, South Africa
[3] Clinton Hlth Access Initiat, Boston, MA USA
[4] Fdn Innovat New Diagnost FIND, Geneva, Switzerland
[5] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02118 USA
基金
美国国家卫生研究院; 荷兰研究理事会; 欧洲研究理事会;
关键词
COVID-19; SARS-CoV-2; diagnostic testing; low- and middle-income countries;
D O I
10.1093/cid/ciac814
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Increasing the availability of antigen rapid diagnostic tests (Ag-RDTs) in low- and middle-income countries (LMICs) is key to alleviating global SARS-CoV-2 testing inequity (median testing rate in December 2021-March 2022 when the Omicron variant was spreading in multiple countries: high-income countries = 600 tests/100 000 people/day; LMICs = 14 tests/100 000 people/day). However, target testing levels and effectiveness of asymptomatic community screening to impact SARS-CoV-2 transmission in LMICs are unclear. Methods We used Propelling Action for Testing and Treating (PATAT), an LMIC-focused agent-based model to simulate coronavirus disease 2019 (COVID-19) epidemics, varying the amount of Ag-RDTs available for symptomatic testing at healthcare facilities and asymptomatic community testing in different social settings. We assumed that testing was a function of access to healthcare facilities and availability of Ag-RDTs. We explicitly modelled symptomatic testing demand from individuals without SARS-CoV-2 and measured impact based on the number of infections averted due to test-and-isolate. Results Testing symptomatic individuals yields greater benefits than any asymptomatic community testing strategy until most symptomatic individuals who sought testing have been tested. Meeting symptomatic testing demand likely requires at least 200-400 tests/100 000 people/day, on average, as symptomatic testing demand is highly influenced by individuals without SARS-CoV-2. After symptomatic testing demand is satisfied, excess tests to proactively screen for asymptomatic infections among household members yield the largest additional infections averted. Conclusions Testing strategies aimed at reducing transmission should prioritize symptomatic testing and incentivizing test-positive individuals to adhere to isolation to maximize effectiveness. SARS-CoV-2 testing strategies aimed at mitigating transmissions should prioritize symptomatic testing over asymptomatic screening. Substantially larger volumes of tests (>100 tests/100 000 people/day) in lower- and middle-income countries are needed to saturate symptomatic testing demand or effectively implement community testing.
引用
收藏
页码:620 / 630
页数:11
相关论文
共 35 条
  • [1] Abbott S., 2021, EPIFORECASTS EPINOW2
  • [2] [Anonymous], 2022, BBC NEWS
  • [3] [Anonymous], 2022, DW NEWS
  • [4] [Anonymous], 2021, ACT ACCELERATOR STRA
  • [5] [Anonymous], 2021, REUTERS
  • [6] The silent and dangerous inequity around access to COVID-19 testing: A call to action Comment
    Batista, Carolina
    Hotez, Peter
    Ben Amor, Yanis
    Kim, Jerome H.
    Kaslow, David
    Lall, Bhavna
    Ergonul, Onder
    Figueroa, J. Peter
    Gursel, Mayda
    Hassanain, Mazen
    Kang, Gagandeep
    Larson, Heidi
    Naniche, Denise
    Sheahan, Timothy
    Wilder-Smith, Annelies
    Shoham, Shmuel
    Sow, Samba O.
    Yadav, Prashant
    Strub-Wourgaft, Nathalie
    Loveday, Sarah-Jane
    Hannay, Emma
    Bottazzi, Maria Elena
    [J]. ECLINICALMEDICINE, 2022, 43
  • [7] The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?
    Boyton, Rosemary J.
    Altmann, Daniel M.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2021, 21 (12) : 762 - 768
  • [8] Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis
    Brummer, Lukas E.
    Katzenschlager, Stephan
    Gaeddert, Mary
    Erdmann, Christian
    Schmitz, Stephani
    Bota, Marc
    Grilli, Maurizio
    Larmann, Jan
    Weigand, Markus A.
    Pollock, Nira R.
    Mace, Aurelien
    Carmona, Sergio
    Ongarello, Stefano
    Sacks, Jilian A.
    Denkinger, Claudia M.
    [J]. PLOS MEDICINE, 2021, 18 (08)
  • [9] An interactive web-based dashboard to track COVID-19 in real time
    Dong, Ensheng
    Du, Hongru
    Gardner, Lauren
    [J]. LANCET INFECTIOUS DISEASES, 2020, 20 (05) : 533 - 534
  • [10] Frecuencia de visitas a los centros de salud y servicios de VIH ofrecidos a los hombres en Malawi
    Dovel, Kathryn
    Balakasi, Kelvin
    Gupta, Sundeep
    Mphande, Misheck
    Robson, Isabella
    Khan, Shaukat
    Amberbir, Alemayehu
    Stilson, Christian
    van Oosterhout, Joep J.
    Doi, Naoko
    Nichols, Brooke E.
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2021, 99 (09) : 618 - 626